Tai P K, Liao J F, Hossler P A, Castor C W, Carter-Su C
Department of Physiology, University of Michigan Medical School, Ann Arbor 48109.
J Biol Chem. 1992 Sep 25;267(27):19579-86.
Connective tissue activating peptide-III (CTAP-III) is a component of platelet alpha-granules which elicits a series of responses in connective tissue cells referred to as activation, including increased glucose consumption and mitogenesis and increased secretion of hyaluronic acid and glycosaminoglycans. As anticipated by a requirement for glucose or glucose precursors in the activation process, an early event following CTAP-III activation of connective tissue cells is an increase in glucose transport. The present study investigates the molecular basis for this increase in glucose transport. Murine 3T3-F442A fibroblasts were found to respond to CTAP-III in a manner similar to human connective tissue cells (synovial cells, chondrocytes, skin fibroblasts). CTAP-III increases the rate of glucose transport to similar extents at 4 and 24 h, and at physiologic (micrograms/ml) concentrations of CTAP-III. A proteolytic cleavage product of recombinant CTAP-III (rCTAP-III-Leu-21 (des-1-15)), also known as neutrophil-activating peptide-2 (NAP-2), was found to be equally effective as CTAP-III, whereas NAP-1/interleukin-8, another member of the CTAP-III super-family, was ineffective in stimulating glucose transport. This contrasts with neutrophil chemotaxis, in which CTAP-III (des-1-15)/NAP-2 acts similarly to NAP-1/interleukin 8 while CTAP-III is ineffective. CTAP-III appears to elicit a different type of glucose transport response than many other growth factors in that its response is sustained (greater than or equal to 24 h) rather than transient (peak approximately 4 h) in confluent as well as in subconfluent cells. Western blot analysis using antibodies to the GLUT-1 glucose transporter revealed an increased level of GLUT-1 protein in response to CTAP-III isoforms that corresponded in magnitude (on a percentage basis) to the increased level of glucose transport. The increased levels of GLUT-1 protein in response to CTAP-III and rCTAP-III-Leu-21 (des-1-15)/NAP-2 were accompanied by an increase in levels of GLUT-1 mRNA of a magnitude sufficient to account for observed increased levels of GLUT-1. These results are consistent with CTAP-III isoforms stimulating glucose transport in connective tissue cells by increasing levels of GLUT-1 mRNA and is one of the few known instances in which increases in levels of GLUT-1 mRNA and protein are sufficient to account for observed increases in glucose transport. They also provide further evidence that CTAP-III (des-1-15)/NAP-2 binds to more than one type of receptor and that CTAP-III acts in a manner different than other well characterized growth factors (e.g. platelet-derived growth factor, transforming growth factor-beta) in that it causes a sustained (greater than or equal to 24 h) elevation in glucose transport in confluent as well as subconfluent cells.
结缔组织激活肽III(CTAP-III)是血小板α颗粒的一种成分,它能在结缔组织细胞中引发一系列被称为激活的反应,包括葡萄糖消耗增加、有丝分裂以及透明质酸和糖胺聚糖分泌增加。正如激活过程中对葡萄糖或葡萄糖前体的需求所预期的那样,CTAP-III激活结缔组织细胞后的一个早期事件是葡萄糖转运增加。本研究探讨了这种葡萄糖转运增加的分子基础。发现小鼠3T3-F442A成纤维细胞对CTAP-III的反应方式与人类结缔组织细胞(滑膜细胞、软骨细胞、皮肤成纤维细胞)相似。CTAP-III在4小时和24小时以及生理浓度(微克/毫升)的CTAP-III下,能使葡萄糖转运速率增加到相似程度。重组CTAP-III的一种蛋白水解裂解产物(rCTAP-III-Leu-21(des-1-15)),也被称为中性粒细胞激活肽-2(NAP-2),被发现与CTAP-III同样有效,而CTAP-III超家族的另一个成员NAP-1/白细胞介素-8在刺激葡萄糖转运方面无效。这与中性粒细胞趋化性形成对比,在中性粒细胞趋化性中,CTAP-III(des-1-15)/NAP-2的作用与NAP-1/白细胞介素8相似,而CTAP-III无效。CTAP-III似乎引发了一种与许多其他生长因子不同类型的葡萄糖转运反应,因为在汇合细胞和亚汇合细胞中,其反应是持续的(大于或等于24小时),而不是短暂的(峰值约4小时)。使用针对GLUT-1葡萄糖转运蛋白的抗体进行的蛋白质印迹分析显示,响应CTAP-III同工型时GLUT-1蛋白水平增加,其幅度(以百分比计)与葡萄糖转运增加的水平相对应。响应CTAP-III和rCTAP-III-Leu-21(des-1-15)/NAP-2时GLUT-1蛋白水平的增加伴随着GLUT-1 mRNA水平的增加,其幅度足以解释观察到的GLUT-1水平的增加。这些结果与CTAP-III同工型通过增加GLUT-1 mRNA水平来刺激结缔组织细胞中的葡萄糖转运一致,这是少数已知的实例之一,其中GLUT-1 mRNA和蛋白水平的增加足以解释观察到的葡萄糖转运增加。它们还提供了进一步的证据,表明CTAP-III(des-1-15)/NAP-2与不止一种类型的受体结合,并且CTAP-III的作用方式与其他特征明确的生长因子(如血小板衍生生长因子、转化生长因子-β)不同,因为它在汇合细胞和亚汇合细胞中导致葡萄糖转运持续(大于或等于24小时)升高。